Oral Dexamethasone as an Intervention for Postoperative Pain and Nausea Management in Total Knee Arthroplasty
1 other identifier
interventional
109
1 country
1
Brief Summary
This study aims to determine if oral dexamethasone provides clinically significant improvement in postoperative outcomes, specifically nausea and pain scores.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_4
Started Aug 2020
Typical duration for phase_4
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 12, 2020
CompletedFirst Posted
Study publicly available on registry
June 16, 2020
CompletedStudy Start
First participant enrolled
August 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2022
CompletedResults Posted
Study results publicly available
September 25, 2026
CompletedSeptember 25, 2026
September 1, 2026
1.1 years
June 12, 2020
February 16, 2024
September 1, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Postoperative Pain
Postoperative pain will be collected via visual analog scale (VAS) scores, from 0 to 10, 0 being no pain, 10 being severe pain. Average VAS score will be reported for each group.
7 days following surgery
Study Arms (2)
Arm B: Oral Dexamethasone
EXPERIMENTALParticipants will be randomly assigned to receive 4 mg Oral Dexamethasone taken twice daily for 4 days
Arm A: Placebo
PLACEBO COMPARATORParticipants will be randomly assigned to receive 4 mg placebo taken twice daily for 4 days
Interventions
Eligibility Criteria
You may qualify if:
- adult patients age 18 and older who will be undergoing joint replacement
You may not qualify if:
- Patients with uncontrolled diabetes ( HbA1C, \>7.5%), impaired hepatic function (Child class, \>B), impaired renal failure (Glomerular filtration rate \<60 mL/min/1.73 m2), chronic narcotic use, alcohol and/or opioid dependence, patients with a known adverse reaction to corticosteroids, and patients unable to give informed consent.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Henry Ford Medical Center - Cottage
Grosse Pointe Farms, Michigan, 48236, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Dr. Jason Davis
- Organization
- Henry Ford Health
Study Officials
- PRINCIPAL INVESTIGATOR
Jason Davis, M.D.
Henry Ford Health System
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 12, 2020
First Posted
June 16, 2020
Study Start
August 1, 2020
Primary Completion
September 1, 2021
Study Completion
December 1, 2022
Last Updated
September 25, 2026
Results First Posted
September 25, 2026
Record last verified: 2026-09